塞内加尔成人恶性疟疾治疗中加用单剂低剂量伯氨喹的安全性及减少配子体携带的疗效:随机对照试验
在塞内加尔G6PD缺乏症高流行区,成人恶性疟疾患者随机接受三种青蒿素联合疗法(ACT)之一,加用或不加用伯氨喹0.25 mg/kg。第7天血红蛋白下降在总体两组相似,但G6PD缺乏患者加用伯氨喹后血红蛋白下降更大;伯氨喹使配子体携带减少73%。
要点
- 伯氨喹单剂0.25 mg/kg可显著减少配子体携带。
- G6PD缺乏患者加用伯氨喹后血红蛋白下降更明显。
- G6PD正常者中一例出现中度严重贫血。
核心结论
- 伯氨喹大幅减少配子体携带,但G6PD缺乏患者加用伯氨喹后第7天血红蛋白下降更大,且一例G6PD正常患者出现中度严重贫血。
研究设计与样本
- 随机对照试验,纳入274例成人恶性疟疾患者,139例仅接受ACT,135例接受ACT加伯氨喹0.25 mg/kg,随访28天。
主要发现
- 第7天血红蛋白平均下降在ACT加伯氨喹组与单用ACT组差异为-0.04 g/dL(95%CI -0.23, 0.31)。
- G6PD缺乏患者中,加用伯氨喹者血红蛋白下降比单用ACT者多0.63 g/dL(95%CI 0.03, 1.24)。
关键数值与推荐
- 伯氨喹剂量为0.25 mg/kg单剂。
- G6PD状态采用快速检测确定。
- 主要终点为第7天血红蛋白变化。
临床怎么用
- 在G6PD缺乏高流行区使用单剂低剂量伯氨喹减少配子体携带时,需先通过快速检测确定G6PD状态并监测血红蛋白。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: More information is needed about the safety of low-dose primaquine in populations where G6PD deficiency is common. METHODS: Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 artemisinin combination therapies (ACTs) with or without primaquine (0.25 mg/kg). Glucose-6-phosphate dehydrogenase (G6PD) status was determined using a rapid test. Patients were followed for 28 days to record hemoglobin concentration, adverse events, and gametocyte carriage. The primary end point was the change in Hb at day 7. RESULTS: In sum, 274 patients were randomized, 139 received an ACT alone, and 135 received an ACT + primaquine. The mean reduction in Hb at day 7 was similar in each group, a difference in the ACT + PQ versus the ACT alone group of -0.04 g/dL (95% confidence interval [CI] -0.23, 0.31), but the effect of primaquine differed according to G6PD status. In G6PD-deficient patients the drop in Hb was 0.63 g/dL (95% CI 0.03, 1.24) greater in those who received primaquine than in those who received an ACT alone. In G6PD-normal patients, the reduction in Hb was 0.22 g/dL (95% CI -0.08, 0.52) less in those who received primaquine (interaction P = .01). One G6PD normal patient who received primaquine developed moderately severe anaemia (Hb < 8 g/dL). Dark urine was more frequent in patients who received primaquine. Primaquine was associated with a 73% (95% CI 24-90) reduction in gametocyte carriage (P = .013). CONCLUSION: Primaquine substantially reduced gametocyte carriage. However, the fall in Hb concentration at day 7 was greater in G6PD-deficient patients who received primaquine than in those who did not and one patient who received primaquine developed moderately severe anemia. CLINICAL TRIAL REGISTRATION: PACTR201411000937373 (www.pactr.org).
引用
- Tine RC, Sylla K, Faye BT, et al. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. Clin Infect Dis. 2017. PMID: 28605472. doi:10.1093/cid/cix355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。